More specifically, Treg ex vivo expansion in SCGM could be used when CLA+ Tregs are needed in cell therapy to home to specific tissues such as with prevention of acute GVHD in skin or gut or minimizing inflammatory skin insults incurred from UV irradiation, allergic dermatitis or from psoriasis [19, 20]. This evidence concerns the gene SELPLG and atopic eczema.